{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:33:26Z","timestamp":1792193606767,"version":"4.4.0"},"reference-count":136,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver condition worldwide, with its burden increasingly recognized among individuals with inflammatory bowel disease (IBD). The complex interplay between chronic intestinal inflammation, metabolic dysregulation, and hepatic pathology has heightened concern about the susceptibility of IBD patients to NAFLD. This study aims to systematically evaluate the global prevalence of NAFLD among patients with IBD and to identify key demographic, geographic, clinical, and pharmacologic factors associated with its development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of four electronic databases\u2014PubMed, Embase, Scopus, and Web of Science\u2014was conducted up to January 21, 2025. Eligible studies included observational research reporting the prevalence of NAFLD in patients with IBD. Random-effects meta-analysis was used to estimate the pooled prevalence of NAFLD. In addition, subgroup analyses and meta-regression were conducted to investigate potential sources of heterogeneity and identify associated demographic, clinical, and geographic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 64 studies comprising 1 532 811 individuals were included. The pooled global prevalence of NAFLD in IBD patients was 25.4% (95% CI: 23.1%-27.8%). Prevalence was higher in adults (26.0%, 95% CI: 24.0%-29.0%) than in pediatric patients (7.0%, 95% CI: 1.0-16.0). Among males and females, prevalence was 32.1% (95% CI: 29.3%-36.0%) and 22.9% (95% CI: 20.2%-25.7%), respectively. Among IBD subtypes, the prevalence was 21.4% in ulcerative colitis (UC; 95% CI: 15.2%-28.3%) and 22.8% in Crohn\u2019s disease (CD; 95% CI: 20.0%-25.0%). Geographic variation was substantial, ranging from 16.0% in Asia (95% CI: 10.0%-25.0%) to 32.0% in Europe (95% CI: 27.0%-38.0%) and Africa (95% CI: 10.0%-57.0%). NAFLD prevalence was also influenced by diagnostic method, with higher rates using transient elastography (38.0%, 95% CI: 27.0%-49.0%) and liver biopsy (37.0%, 95% CI: 17.0%-59.0%). By disease location, the highest NAFLD prevalence in CD was in patients with upper GI involvement (67.0%, 95% CI: 1%-99.0%), while the lowest was in ileo-colonic disease (21.0%, 95% CI: 12.0%-32.0%). For UC, prevalence ranged from 27.0% (95% CI: 17.0%-39.0%) in left-sided colitis to 18.0% (95% CI: 8.0%-29.0%) in proctosigmoiditis. No significant association with NAFLD was observed for any IBD medication analyzed, including 5-aminosalicylic acid (5-ASA; OR: 0.85, 95% CI: 0.69-1.05; P\u2009=\u2009.15), azathioprine (OR: 1.04, 95% CI: 0.78-1.40; P\u2009=\u2009.76), vedolizumab (OR: 0.81, 95% CI: 0.45-1.44; P\u2009=\u2009.48), Ustekinumab (OR: 1.03, 95% CI: 0.58-1.82; P\u2009=\u2009.90), anti-TNF agents (OR: 1.20, 95% CI: 0.85-1.68; P\u2009=\u2009.28), and systemic corticosteroids (OR: 1.43, 95% CI: 0.89-2.32; P\u2009=\u2009.13).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NAFLD is a common comorbidity among patients with IBD, affecting over one in four individuals, with higher prevalence observed in adults, males, and certain geographic regions. Variation by diagnostic modality and disease location was also noted; however, these subgroup findings are based on limited data and should be interpreted with caution. Overall, the results highlight the importance of incorporating liver health screening into routine IBD management, particularly for high-risk populations, and underscore the need for future prospective studies to refine risk stratification and management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf226","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:34:04Z","timestamp":1757417644000},"page":"350-374","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: An Updated Global Systematic Review and Meta-Analysis of over 1.5 Million Individuals"],"prefix":"10.1093","volume":"32","author":[{"given":"Narsimha","family":"Keetha Rao","sequence":"first","affiliation":[{"name":"Ohio Kidney and Hypertension Center , Middleburg Hts, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Ghodous","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Gurram","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Khorasani","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudhan","family":"Ponnala","sequence":"additional","affiliation":[{"name":"Pennstate Health Holy Spirit Hospital , Camp Hill, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Habibi","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Agyeman","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Medicine, Loma Linda University Health , Loma Linda, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Saberian","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Hormozgan University of Medical Sciences , Bandar Abbas,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pubali","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NYC HHC\/Metropolitan Hospital, New York , NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Letafatkar","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Yale New Haven Health Bridgeport Hospital , Bridgeport, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Sahli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Arnot Ogden Medical Center , Elmira, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Amani-Beni","sequence":"additional","affiliation":[{"name":"Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences , Isfahan,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Darouei","sequence":"additional","affiliation":[{"name":"Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences , Isfahan,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yussif","family":"Issaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Yale New Haven Health Bridgeport Hospital , Bridgeport, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Sandilya Balivada","sequence":"additional","affiliation":[{"name":"Department of Computer Science, University of Massachusetts Boston , Boston, MA 02125,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farahnaz","family":"Joukar","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Nasrollahizadeh","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Tehran University of Medical Sciences , Tehran,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Ogazi","sequence":"additional","affiliation":[{"name":"CSO Float Registered Nurse Yale New Haven Health , Stratford, CT 06614,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Amin Karimi","sequence":"additional","affiliation":[{"name":"School of Medicine, Shahid Beheshti University of Medical Sciences , Tehran,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Department of Medicine, Riverside University Health System Medical Center , Moreno Valley, CA 92555,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Hossein","family":"Keivanlou","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Javad","family":"Khosousi","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]},{"name":"Section of Digestive Diseases , Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed Mohammad","family":"Hashemi","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Hormozgan University of Medical Sciences , Bandar Abbas,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4985-2899","authenticated-orcid":false,"given":"Ehsan","family":"Amini-Salehi","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep S","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Yale New Haven Health Bridgeport Hospital , Bridgeport, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026013010483249400_izaf226-B1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"2026013010483249400_izaf226-B2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2026013010483249400_izaf226-B3","doi-asserted-by":"crossref","first-page":"597648","DOI":"10.3389\/fendo.2020.597648","article-title":"Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies","volume":"11","author":"Luci","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026013010483249400_izaf226-B4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/medicina58050641","article-title":"Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue","volume":"58","author":"Petrescu","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"2026013010483249400_izaf226-B5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"22","author":"Dharmalingam","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"2026013010483249400_izaf226-B6","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.3390\/ijms24119677","article-title":"Type 2 diabetes mellitus, non-alcoholic fatty liver disease, and metabolic repercussions: the vicious cycle and its interplay with inflammation","volume":"24","author":"Frankowski","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026013010483249400_izaf226-B7","first-page":"e41120","article-title":"Advancements in inflammatory bowel disease: a narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation","volume":"15","author":"Muzammil","year":"2023","journal-title":"Cureus"},{"key":"2026013010483249400_izaf226-B8","first-page":"72","article-title":"Inflammatory bowel disease","volume":"113","author":"Wehkamp","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"2026013010483249400_izaf226-B9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"2026013010483249400_izaf226-B10","volume-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease","author":"Malik","year":"2025"},{"key":"2026013010483249400_izaf226-B11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"27","author":"Lin","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B12","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1007\/s10620-020-06588-6","article-title":"Nonalcoholic fatty liver disease is common in ibd patients however progression to hepatic fibrosis by noninvasive markers is rare","volume":"66","author":"Ritaccio","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026013010483249400_izaf226-B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41419-017-0124-2","article-title":"Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease","volume":"9","author":"Sartini","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026013010483249400_izaf226-B14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.immuni.2018.12.015","article-title":"Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and ROR\u03b3t(+) regulatory T cells and exacerbate colitis in mice","volume":"50","author":"Britton","year":"2019","journal-title":"Immunity"},{"key":"2026013010483249400_izaf226-B15","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.3390\/nu14245323","article-title":"Gut microbiota in non-alcoholic fatty liver disease patients with inflammatory bowel diseases: a complex interplay","volume":"14","author":"Abenavoli","year":"2022","journal-title":"Nutrients"},{"key":"2026013010483249400_izaf226-B16","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.3390\/nu13082772","article-title":"The other side of malnutrition in inflammatory bowel disease (IBD): non-alcoholic fatty liver disease","volume":"13","author":"Gibiino","year":"2021","journal-title":"Nutrients"},{"key":"2026013010483249400_izaf226-B17","doi-asserted-by":"crossref","first-page":"i932","DOI":"10.1093\/ecco-jcc\/jjae190.0601","article-title":"P0427 Nutritional factors associated with the presence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD)","volume":"19","author":"Castelhano","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026013010483249400_izaf226-B18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2021.07.026","article-title":"Systemic inflammation in preclinical ulcerative colitis","volume":"161","author":"Bergemalm","year":"2021","journal-title":"Gastroenterology"},{"key":"2026013010483249400_izaf226-B19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2017.09.008","article-title":"Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease","volume":"69","author":"Bosch","year":"2017","journal-title":"Hum Pathol"},{"key":"2026013010483249400_izaf226-B20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/ibd\/izy051","article-title":"Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors","volume":"24","author":"Principi","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MEG.0000000000000350","article-title":"Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment","volume":"27","author":"Schr\u00f6der","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026013010483249400_izaf226-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2026013010483249400_izaf226-B23","author":"Institute TJB","year":"2017"},{"key":"2026013010483249400_izaf226-B24","author":"Institute TJB","year":"2017"},{"key":"2026013010483249400_izaf226-B25","author":"Institute JB","year":"2017"},{"key":"2026013010483249400_izaf226-B26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/life14101226","article-title":"Metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel diseases: a pilot study","volume":"14","author":"Abenavoli","year":"2024","journal-title":"Life"},{"key":"2026013010483249400_izaf226-B27","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/medicina59111935","article-title":"Ultrasound prevalence and clinical features of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a real-life cross-sectional study","volume":"59","author":"Abenavoli","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026013010483249400_izaf226-B28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.14740\/gr1509","article-title":"Burden and predictors of non-alcoholic fatty liver disease in a retrospective cohort of patients with Crohn\u2019s disease","volume":"15","author":"Abomhya","year":"2022","journal-title":"Gastroenterology Res"},{"key":"2026013010483249400_izaf226-B29","doi-asserted-by":"crossref","first-page":"e0206450","DOI":"10.1371\/journal.pone.0206450","article-title":"Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: a case-control study","volume":"13","author":"Adams","year":"2018","journal-title":"PLoS One"},{"key":"2026013010483249400_izaf226-B30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15537\/smj.2025.46.1.20240758","article-title":"Hepatobiliary manifestations of inflammatory bowel disease in Saudi Arabia: a retrospective analysis","volume":"46","author":"Aljiffry","year":"2025","journal-title":"Saudi Med J"},{"key":"2026013010483249400_izaf226-B31","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/MEG.0000000000001319","article-title":"Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference","volume":"31","author":"Arieira","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026013010483249400_izaf226-B32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12664-015-0598-8","article-title":"Extraintestinal manifestations in inflammatory bowel disease: prevalence and predictors in Indian patients","volume":"34","author":"Bandyopadhyay","year":"2015","journal-title":"Indian J Gastroenterol"},{"key":"2026013010483249400_izaf226-B33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004836-200305000-00012","article-title":"Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center","volume":"36","author":"Bargiggia","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"2026013010483249400_izaf226-B34","first-page":"299","article-title":"Non-alcoholic fatty liver disease (NAFLD) and obesity in inflammatory bowel disease (IBD) patients in Gorgan","volume":"15","author":"Besharat","year":"2024","journal-title":"Caspian J Intern Med"},{"key":"2026013010483249400_izaf226-B35","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12876-023-02988-w","article-title":"Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores","volume":"23","author":"Capela","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2026013010483249400_izaf226-B37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/CGast.S13125","article-title":"Liver function test abnormalities in patients with inflammatory bowel diseases: a hospital-based survey","volume":"7","author":"Cappello","year":"2014","journal-title":"Clin Med Insights Gastroenterol"},{"key":"2026013010483249400_izaf226-B38","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3390\/jcm10143062","article-title":"Insulin resistance is not increased in inflammatory bowel disease patients but is related to non-alcoholic fatty liver disease","volume":"10","author":"Carrillo-Palau","year":"2021","journal-title":"J Clin Med"},{"key":"2026013010483249400_izaf226-B39","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MPG.0000000000003023","article-title":"Evaluation of nonalcoholic fatty liver disease in pediatric patients with inflammatory bowel disease","volume":"72","author":"Cohen","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026013010483249400_izaf226-B40","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.3390\/jcm10225359","article-title":"Liver pathology in children with diagnosed inflammatory bowel disease\u2014a single center experience","volume":"10","author":"Daniluk","year":"2021","journal-title":"J Clin Med"},{"key":"2026013010483249400_izaf226-B41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/00365520701800266","article-title":"Histopathology of liver biopsies from a thiopurine-na\u00efve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia","volume":"43","author":"De Boer","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"2026013010483249400_izaf226-B42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4292\/wjgpt.v11.i3.48","article-title":"Hepatobiliary manifestations in children with inflammatory bowel disease: a single-center experience in a low\/middle income country","volume":"11","author":"El-Shabrawi","year":"2020","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2026013010483249400_izaf226-B43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12876-019-0967-3","article-title":"Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study","volume":"19","author":"Fousekis","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"2026013010483249400_izaf226-B44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/MIB.0000000000001085","article-title":"Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease","volume":"23","author":"Glassner","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B45","doi-asserted-by":"crossref","first-page":"101293","DOI":"10.1016\/j.jceh.2023.10.004","article-title":"Prevalence, predictors, and impact of hepatic steatosis in patients with ulcerative colitis: a prospective observational cohort study","volume":"14","author":"Gupta","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"2026013010483249400_izaf226-B46","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a cross-sectional and longitudinal analysis","volume":"26","author":"Hoffmann","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2026013010483249400_izaf226-B47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12876-022-02238-5","article-title":"Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn\u2019s disease","volume":"22","author":"Hong","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"2026013010483249400_izaf226-B48","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.3390\/diagnostics13203268","article-title":"Metabolic dysfunction-associated fatty liver disease in taiwanese patients with inflammatory bowel disease: a study in patients with clinical remission","volume":"13","author":"Hsiao","year":"2023","journal-title":"Diagnostics"},{"key":"2026013010483249400_izaf226-B49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.5009\/gnl220409","article-title":"Hepatic steatosis but not fibrosis is independently associated with poor outcomes in patients with inflammatory bowel disease","volume":"18","author":"Hyun","year":"2024","journal-title":"Gut Liver"},{"key":"2026013010483249400_izaf226-B50","doi-asserted-by":"crossref","first-page":"otad004","DOI":"10.1093\/crocol\/otad004","article-title":"Nonalcoholic fatty liver disease increases cardiovascular risk in inflammatory bowel diseases","volume":"5","author":"Kablawi","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026013010483249400_izaf226-B51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1159\/000506938","article-title":"Sarcopenia is a new risk factor of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"38","author":"Kang","year":"2020","journal-title":"Dig Dis"},{"key":"2026013010483249400_izaf226-B52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5472\/marumj.570907","article-title":"Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter","volume":"32","author":"Kan\u0131","year":"2019","journal-title":"Marmara Med J"},{"key":"2026013010483249400_izaf226-B53","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3748\/wjg.v23.i22.4102","article-title":"Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study","volume":"23","author":"Koller","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2026013010483249400_izaf226-B54","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v9.i10.2300","article-title":"Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study","volume":"9","author":"Lakatos","year":"2003","journal-title":"World J Gastroenterol"},{"key":"2026013010483249400_izaf226-B55","first-page":"10633","article-title":"High incidence of non-alcoholic fatty liver disease in patients with Crohn\u2019s disease but not ulcerative colitis","volume":"10","author":"Li","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"2026013010483249400_izaf226-B56","first-page":"283","article-title":"Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"2026013010483249400_izaf226-B57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00384-021-04065-8","article-title":"Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up","volume":"37","author":"van Lingen","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"2026013010483249400_izaf226-B58","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.3748\/wjg.v26.i47.7528","article-title":"Prevalence and associated factors of obesity in inflammatory bowel disease: a case-control study","volume":"26","author":"Losurdo","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2026013010483249400_izaf226-B59","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.3748\/wjg.v25.i37.5676","article-title":"Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: beyond the natural history","volume":"25","author":"Magr\u00ec","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2026013010483249400_izaf226-B60","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/SGA.0000000000000461","article-title":"Ulcerative colitis as an independent risk factor for hepatic steatosis","volume":"43","author":"Mancina","year":"2020","journal-title":"Gastroenterol Nurs"},{"key":"2026013010483249400_izaf226-B61","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/liv.15003","article-title":"Anti-TNF\u03b1 treatment in Crohn\u2019s disease: impact on hepatic steatosis, gut-derived hormones and metabolic status","volume":"41","author":"Manka","year":"2021","journal-title":"Liver Int"},{"key":"2026013010483249400_izaf226-B62","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/ibd\/izad175","article-title":"Inflammatory bowel disease is an independent risk factor for metabolic dysfunction\u2013associated steatotic liver disease in lean individuals","volume":"30","author":"Mart\u00ednez-Dom\u00ednguez","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejim.2023.10.019","article-title":"Crohn\u2032 s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease","volume":"120","author":"Mart\u00ednez-Dom\u00ednguez","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026013010483249400_izaf226-B64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/pch\/pxad065","article-title":"Paediatric obesity and Crohn\u2019s disease: a descriptive review of disease phenotype and clinical course","volume":"29","author":"McCoy","year":"2024","journal-title":"Paediatr Child Health"},{"key":"2026013010483249400_izaf226-B65","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/ibd\/izz324","article-title":"Derivation and internal validation of a clinical prediction tool to predict nonalcoholic fatty liver disease in patients with Crohn\u2019s disease","volume":"26","author":"McHenry","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajg.2012.06.005","article-title":"Hepatobiliary disorders among na\u00efve patients with ulcerative colitis in Upper Egypt","volume":"13","author":"Morsy","year":"2012","journal-title":"Arab J Gastroenterol"},{"key":"2026013010483249400_izaf226-B67","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5217\/ir.2023.00035","article-title":"Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study","volume":"21","author":"Nagata","year":"2023","journal-title":"Intest Res"},{"key":"2026013010483249400_izaf226-B68","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3109\/00365521.2014.921326","article-title":"National trends and inpatient outcomes of inflammatory bowel disease patients with concomitant chronic liver disease","volume":"49","author":"Nguyen","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"2026013010483249400_izaf226-B69","doi-asserted-by":"crossref","first-page":"e20231321","DOI":"10.1590\/1806-9282.20231321","article-title":"Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center","volume":"70","author":"Oliveira","year":"2024","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"2026013010483249400_izaf226-B70","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography","volume":"25","author":"Saroli Palumbo","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B71","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00261-011-9832-8","article-title":"Crohn\u2019s disease: prevalence of intestinal and extraintestinal manifestations detected by computed tomography enterography with water enema","volume":"37","author":"Paparo","year":"2012","journal-title":"Abdom Imaging"},{"key":"2026013010483249400_izaf226-B72","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/00365521.2015.1064995","article-title":"Prevalence and prognostic value of hepatic histological alterations in patients with Crohn\u2019s disease","volume":"50","author":"Ribaldone","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2026013010483249400_izaf226-B73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cgh.2022.01.039","article-title":"Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors","volume":"21","author":"Rodriguez-Duque","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010483249400_izaf226-B74","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/hepr.12828","article-title":"Significance of non-alcoholic fatty liver disease in Crohn\u2019s disease: a retrospective cohort study","volume":"47","author":"Sagami","year":"2017","journal-title":"Hepatol Res"},{"key":"2026013010483249400_izaf226-B75","doi-asserted-by":"crossref","first-page":"7604939","DOI":"10.1155\/2019\/7604939","article-title":"Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients","volume":"2019","author":"Silva","year":"2019","journal-title":"Biomed Res Int"},{"key":"2026013010483249400_izaf226-B76","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/ibd\/izy128","article-title":"IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with Crohn\u2019s disease","volume":"24","author":"Simon","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B77","first-page":"646","article-title":"Influence of nonalcoholic fatty liver disease on inflammatory bowel disease hospitalizations in the United States","volume":"36","author":"Soni","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"2026013010483249400_izaf226-B78","doi-asserted-by":"crossref","first-page":"e279-85","DOI":"10.1016\/j.crohns.2012.10.015","article-title":"Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"7","author":"Sourianarayanane","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2026013010483249400_izaf226-B79","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.crohns.2013.12.006","article-title":"Detection of liver injury in IBD using transient elastography","volume":"8","author":"Thin","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026013010483249400_izaf226-B80","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.3390\/jcm11195959","article-title":"Screening for liver steatosis and fibrosis in patients with inflammatory bowel disease using vibration controlled transient elastography with controlled attenuation parameter","volume":"11","author":"Trifan","year":"2022","journal-title":"J Clin Med"},{"key":"2026013010483249400_izaf226-B81","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/jcm11092623","article-title":"Hepatic steatosis and fibrosis in chronic inflammatory bowel disease","volume":"11","author":"Veltkamp","year":"2022","journal-title":"J Clin Med"},{"key":"2026013010483249400_izaf226-B82","doi-asserted-by":"crossref","first-page":"19954","DOI":"10.1038\/s41598-021-98843-7","article-title":"Hepatobiliary phenotype of individuals with chronic intestinal disorders","volume":"11","author":"Voss","year":"2021","journal-title":"Sci Rep"},{"key":"2026013010483249400_izaf226-B83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1665-2681(19)31615-1","article-title":"Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis","volume":"9","author":"Yamamoto-Furusho","year":"2010","journal-title":"Ann Hepatol"},{"key":"2026013010483249400_izaf226-B84","doi-asserted-by":"crossref","first-page":"e0252286","DOI":"10.1371\/journal.pone.0252286","article-title":"Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: a Taiwanese retrospective cohort study","volume":"16","author":"Yen","year":"2021","journal-title":"PLoS One"},{"key":"2026013010483249400_izaf226-B85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.dld.2024.11.002","article-title":"Mortality risk associated with MASLD, MASLD type and different cardiometabolic risk factors in IBD patients: a long-term prospective cohort study","volume":"57","author":"Zhang","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026013010483249400_izaf226-B86","doi-asserted-by":"crossref","first-page":"1517462","DOI":"10.3389\/fmed.2025.1517462","article-title":"Prevalence of non-alcoholic fatty liver disease among inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026013010483249400_izaf226-B87","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/nu15214507","article-title":"Systematic review and meta-analysis: prevalence of non-alcoholic fatty liver disease and liver fibrosis in patients with inflammatory bowel disease","volume":"15","author":"Navarro","year":"2023","journal-title":"Nutrients"},{"key":"2026013010483249400_izaf226-B88","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026013010483249400_izaf226-B89","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ibd\/izz043","article-title":"Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"25","author":"Zou","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B90","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"key":"2026013010483249400_izaf226-B91","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.3390\/nu12103166","article-title":"Pediatric non-alcoholic fatty liver disease: nutritional origins and potential molecular mechanisms","volume":"12","author":"Mandala","year":"2020","journal-title":"Nutrients"},{"key":"2026013010483249400_izaf226-B92","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2014A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"2026013010483249400_izaf226-B93","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3748\/wjg.v28.i27.3314","article-title":"Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease","volume":"28","author":"Ristic-Medic","year":"2022","journal-title":"World J Gastroenterol"},{"key":"2026013010483249400_izaf226-B94","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3390\/nu15122749","article-title":"Global impacts of western diet and its effects on metabolism and health: a narrative review","volume":"15","author":"Clemente-Su\u00e1rez","year":"2023","journal-title":"Nutrients"},{"key":"2026013010483249400_izaf226-B95","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"2026013010483249400_izaf226-B96","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"2026013010483249400_izaf226-B97","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","article-title":"Current status of imaging in nonalcoholic fatty liver disease","volume":"10","author":"Li","year":"2018","journal-title":"World J Hepatol"},{"key":"2026013010483249400_izaf226-B98","doi-asserted-by":"crossref","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"key":"2026013010483249400_izaf226-B99","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.clinthera.2021.07.012","article-title":"Current and emerging biomarkers and imaging modalities for nonalcoholic fatty liver disease: clinical and research applications","volume":"43","author":"Hydes","year":"2021","journal-title":"Clin Ther"},{"key":"2026013010483249400_izaf226-B100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"2026013010483249400_izaf226-B101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"2026013010483249400_izaf226-B102","first-page":"614","article-title":"The link between NAFLD and Metabolic Syndrome","volume":"13","author":"Radu","year":"2023","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"2026013010483249400_izaf226-B103","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jgh.13219","article-title":"Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease","volume":"31","author":"de L\u00e9dinghen","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"2026013010483249400_izaf226-B104","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/ibd\/izy030","article-title":"Improving quality in the care of patients with inflammatory bowel diseases","volume":"24","author":"Egberg","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B105","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00535-023-02021-7","article-title":"MAFLD: an optimal framework for understanding liver cancer phenotypes","volume":"58","author":"Crane","year":"2023","journal-title":"J Gastroenterol"},{"key":"2026013010483249400_izaf226-B106","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/liv.15142","article-title":"Meaning of non-overlapping patients between the MAFLD and NAFLD definitions","volume":"42","author":"Chan","year":"2022","journal-title":"Liver Int"},{"key":"2026013010483249400_izaf226-B107","first-page":"288","article-title":"Lean MASLD and IBD: exploring the intersection of metabolic dysfunction and the gut-liver axis","volume":"15","author":"Rotaru","year":"2025","journal-title":"Life (Basel)"},{"key":"2026013010483249400_izaf226-B108","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10238-024-01553-3","article-title":"Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort","volume":"25","author":"Elsabaawy","year":"2025","journal-title":"Clin Exp Med"},{"key":"2026013010483249400_izaf226-B109","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3350\/cmh.2023.0277","article-title":"Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced modernity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2026013010483249400_izaf226-B110","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/ph17111432","article-title":"The effect of biologic agents on steatotic liver disease in patients with inflammatory bowel disease: a prospective, open-label comparative trial","volume":"17","author":"Papaefthymiou","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026013010483249400_izaf226-B111","doi-asserted-by":"crossref","first-page":"e000349","DOI":"10.1136\/bmjgast-2019-000349","article-title":"Antitumour necrosis factor-\u03b1 agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort","volume":"7","author":"Tang","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"2026013010483249400_izaf226-B112","first-page":"463","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"2026013010483249400_izaf226-B113","first-page":"5818","article-title":"Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review","volume":"25","author":"Spagnuolo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026013010483249400_izaf226-B114","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.livres.2022.05.002","article-title":"Non-alcoholic fatty liver disease development: a multifactorial pathogenic phenomena","volume":"6","author":"Bashir","year":"2022","journal-title":"Liver Res"},{"key":"2026013010483249400_izaf226-B115","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/1744666X.2025.2514605","article-title":"Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences","volume":"21","author":"Grueso Navarro","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"2026013010483249400_izaf226-B116","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/metabo13030378","article-title":"What do NAFLD, liver fibrosis, and inflammatory bowel disease have in common? review of the current literature","volume":"13","author":"Jarmakiewicz-Czaja","year":"2023","journal-title":"Metabolites"},{"key":"2026013010483249400_izaf226-B117","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.3390\/ijms25063278","article-title":"Inflammatory bowel diseases and non-alcoholic fatty liver disease: piecing a complex puzzle together","volume":"25","author":"Maresca","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026013010483249400_izaf226-B118","first-page":"1622","article-title":"Gut-liver axis and non-alcoholic fatty liver disease: a vicious circle of dysfunctions orchestrated by the gut microbiome","volume":"11","author":"Pezzino","year":"2022","journal-title":"Biology (Basel)"},{"key":"2026013010483249400_izaf226-B119","doi-asserted-by":"crossref","first-page":"1365294","DOI":"10.3389\/fphar.2024.1365294","article-title":"The gut-liver axis in fatty liver disease: role played by natural products","volume":"15","author":"Ming","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026013010483249400_izaf226-B120","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"2026013010483249400_izaf226-B121","article-title":"Gut\u2011liver axis in liver disease: from basic science to clinical treatment (Review)","volume":"31","author":"Wang","year":"2025","journal-title":"Mol Med Rep"},{"key":"2026013010483249400_izaf226-B122","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/medicina60071068","article-title":"A comprehensive review of dietary approaches in maintaining remission of inflammatory bowel diseases in adults","volume":"60","author":"Istratescu","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"2026013010483249400_izaf226-B123","first-page":"469","article-title":"Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population","volume":"31","author":"Principi","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2026013010483249400_izaf226-B124","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/hsc.13755","article-title":"Food and inflammatory bowel diseases: a scoping review on the impact of food on patients\u2019 psychosocial quality of life","volume":"30","author":"Palamenghi","year":"2022","journal-title":"Health Soc Care Community"},{"key":"2026013010483249400_izaf226-B125","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/gutjnl-2024-331914","article-title":"Heavy arch: from inflammatory bowel diseases to metabolic disorders","volume":"73","author":"Adolph","year":"2024","journal-title":"Gut"},{"key":"2026013010483249400_izaf226-B126","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s41043-025-00860-z","article-title":"Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale","volume":"44","author":"Janani","year":"2025","journal-title":"J Health Popul Nutr"},{"key":"2026013010483249400_izaf226-B127","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/pathogens8030126","article-title":"Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome","volume":"8","author":"Khan","year":"2019","journal-title":"Pathogens"},{"key":"2026013010483249400_izaf226-B128","first-page":"179","volume-title":"Progress in Molecular Biology and Translational \u00adScience","author":"Lal","year":"2022"},{"key":"2026013010483249400_izaf226-B129","doi-asserted-by":"crossref","first-page":"1435030","DOI":"10.3389\/fmed.2025.1435030","article-title":"Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence","volume":"12","author":"Farah","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026013010483249400_izaf226-B130","doi-asserted-by":"crossref","first-page":"1375654","DOI":"10.3389\/fimmu.2024.1375654","article-title":"Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease","volume":"15","author":"Wei","year":"2024","journal-title":"Front Immunol"},{"key":"2026013010483249400_izaf226-B131","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/biomedicines10010194","article-title":"Detailed molecular mechanisms involved in drug-induced non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: an update","volume":"10","author":"Di Pasqua","year":"2022","journal-title":"Biomedicines"},{"key":"2026013010483249400_izaf226-B132","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/MEG.0000000000001144","article-title":"Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Lapumnuaypol","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026013010483249400_izaf226-B133","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","article-title":"Progression of non-alcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study","volume":"79","author":"Simon","year":"2023","journal-title":"J Hepatol"},{"key":"2026013010483249400_izaf226-B134","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/ibd\/izab199","article-title":"The impact of NAFLD on hospitalization outcomes in patients with inflammatory bowel diseases: nationwide analysis","volume":"28","author":"Noorian","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010483249400_izaf226-B135","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/MEG.0000000000002607","article-title":"The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review","volume":"35","author":"Boustany","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026013010483249400_izaf226-B136","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/cancers15133367","article-title":"Liver fibrosis in non-alcoholic fatty liver disease and progression to hepatocellular carcinoma in patients with inflammatory bowel disease: a systematic review","volume":"15","author":"Mart\u00ednez-Dom\u00ednguez","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/2\/350\/64739149\/izaf226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/2\/350\/64739149\/izaf226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:48:53Z","timestamp":1769788133000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/2\/350\/8292694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":136,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf226","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,17]]}}}